Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes
NCT ID: NCT01479933
Last Updated: 2013-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
73 participants
INTERVENTIONAL
2011-09-30
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this trial is to investigate the effects of two different daily doses of vitamin D on glucose metabolism in men 60 years of age or older and who are vitamin D deficient, have a high body mass index and at least two characteristics of cardio-metabolic syndrome.
Altogether 102 subjects with low serum calcidiol (\<60 nmol/L) will be recruited and randomized to one of the three groups: 1) 40 µg/d vitamin D3, 2) 80 µg/d vitamin D3 or 3) placebo. The supplementation period will last for 6 months from September 2011 to March 2012.
The main hypotheses of the trial are: (1.) Vitamin D supplementation will improve glucose and insulin metabolism in people with a low baseline vitamin D status, in a dose-dependent manner. (2.) Vitamin D supplementation will have an effect on the expression of genes involved in glucose and insulin metabolism and inflammation. (3.) Vitamin D supplementation will have an effect on epigenetic changes in key genes participating in vitamin D metabolism.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Vitamin D Deficiency and Vitamin D Supplementation on Glucose Metabolism
NCT00749918
Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome
NCT01237769
Vitamin D in Minorities With Prediabetes
NCT00876928
Vitamin D Supplementation and and Glycemic Indexes
NCT03478475
Effect of Vitamin D Supplementation on Glucose Tolerance in Subjects at Risk for Diabetes With Low Vitamin D.
NCT01726777
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin D 40
Vitamin D3 40 micrograms (1600 IU) per day
Vitamin D3
Vitamin D3 40 micrograms (1600 IU) per day
Vitamin D 80
Vitamin D3 80 micrograms (3200 IU) per day
Vitamin D 80
Vitamin D3 80 micrograms (3200 IU) per day
Placebo
Placebo
Inactive placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D3
Vitamin D3 40 micrograms (1600 IU) per day
Placebo
Inactive placebo
Vitamin D 80
Vitamin D3 80 micrograms (3200 IU) per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum calcidiol \<75 nmol/L
* Body mass index 25-35 kg/m2
* Impaired fasting glucose or impaired glucose tolerance (fasting glucose 5.6-7.0 mmol/L or 2h oral glucose tolerance test glucose 7.8-11.0 mmol/L)
Exclusion Criteria
* Any chronic disease or therapy which may mask or interact with the investigated effects (such as diabetes or systemic corticosteroid therapy)
* Any disease or state that raises a vitamin D related safety concern (such as chronic liver, thyroid or kidney disease, hypercalcemia, sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or Wegener's granulomatosis)
* Use of supplements yielding vitamin D over 20 µg/d and unwillingness to discontinue the use.
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academy of Finland
OTHER
Juho Vainio Foundation
OTHER
Finnish Foundation for Cardiovascular Research
OTHER
Diabetes Research Foundation, Finland
OTHER
University of Eastern Finland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tomi-Pekka Tuomainen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tomi-Pekka Tuomainen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Eastern Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Eastern Finland, Kuopio Campus
Kuopio, Kuopio, Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ryynanen J, Neme A, Tuomainen TP, Virtanen JK, Voutilainen S, Nurmi T, de Mello VD, Uusitupa M, Carlberg C. Changes in vitamin D target gene expression in adipose tissue monitor the vitamin D response of human individuals. Mol Nutr Food Res. 2014 Oct;58(10):2036-45. doi: 10.1002/mnfr.201400291. Epub 2014 Jul 28.
Related Links
Access external resources that provide additional context or updates about the study.
University of Eastern Finland
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VitDmet
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.